Combining our first-in-class platform & the science of synthetic genomics to transform RNA therapy.
Chimeron Bio is building a portfolio of self-amplifying RNA therapeutics to bring more effective gene therapies and personalized medicines to patients.
Chimeron Bio’s unique ChaESAR platform leverages chimera encased self-amplifying RNA (saRNA) to achieve superior expression and broader dynamic range compared to other leading messenger RNA (mRNA) technologies.
Building on the Modern Science of RNA to Create First-in-Class saRNA Drugs for Patients with Unmet Needs
We are developing a compelling portfolio of innovative and personalized saRNA-based medicines for people with serious diseases including cancer, infectious diseases, and rare genetic disorders, using our technology to achieve superior patient response at a lower dose.
Chimeron Bio Announces Appointment of Dr. Robert (Bob) Willette to its Scientific Advisory Board
PHILADELPHIA–Chimeron Bio, an RNA therapy company based in Philadelphia pioneering a novel class of RNA therapeutics and vaccines, today announced the appointment of Dr. Robert (Bob) Willette to its Scientific Advisory Board. As a leader in metabolic disorders Dr. Willette will provide counsel on drug discovery and development strategies to propel the advancement of Chimeron […]
Harnessing Ancient Viral Biology to Advance New Age RNA Therapies
RNA, once viewed as passive carriers of genetic information, is arguably the most versatile and potent regulator of biological processes and diseases. Developing RNA as drug agents for the treatment of complex diseases such as cancer and genetic disorders is therefore, an exciting area of research. While RNA therapeutics has the potential to change the […]
